Skip to main content
. 2018 Jun 8;18:36. doi: 10.1186/s12902-018-0267-x

Fig. 1.

Fig. 1

Schematic overview of nivolumab-treated patients with malignant melanoma

The inclusion criteria and numbers of each group are described. irAE, immune-related adverse event. *Patients with current active thyroid dysfunction and without evaluation of thyroid function were excluded